The Experts below are selected from a list of 249 Experts worldwide ranked by ideXlab platform
Yasuo Terauchi - One of the best experts on this subject based on the ideXlab platform.
-
comparison of azelnidipine and Trichlormethiazide in japanese type 2 diabetic patients with hypertension the coat randomized controlled trial
PLOS ONE, 2015Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo TerauchiAbstract:Objective This study compared the efficacy and safety of azelnidipine with that of Trichlormethiazide in Japanese type 2 diabetic patients with hypertension.
-
Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial
2015Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo TerauchiAbstract:ObjectiveThis study compared the efficacy and safety of azelnidipine with that of Trichlormethiazide in Japanese type 2 diabetic patients with hypertension.MethodsIn a multicenter, open-label trial, 240 patients with adequately controlled diabetes (HbA1c ≤ 7.0%) under lifestyle modification and/or administration of hypoglycemic agents and inadequately controlled hypertension (systolic blood pressure [sBP] ≥ 130 mmHg or diastolic blood pressure [dBP] ≥ 80 mmHg) who were being treated with olmesartan were enrolled. Participants were randomly assigned to an azelnidipine group or a Trichlormethiazide group and were followed up for 48 weeks. Main outcome measure was the difference in the change in HbA1c levels from the baseline values at 48 weeks between these two groups.ResultsOf the 240 subjects that were enrolled, 209 subjects (azelnidipine group: 103 patients, Trichlormethiazide group: 106 patients) completed this trial. At 48 weeks, the following changes were observed in the azelnidipine and Trichlormethiazide groups, respectively: HbA1c levels, 0.19 ± 0.52% and 0.19 ± 0.54%; sBP/dBP, -10.7 ± 9.6/-6.6 ± 6.6 mmHg and -7.1 ± 7.7/-3.3 ± 6.1 mmHg (P < 0.001 for both sBP and dBP). In both groups, dizziness (12 patients [11.7%] and 16 patients [15.1%]) and edema (16 patients [15.5%] and 7 patients [6.6%], P = 0.047) were observed during the 48-week follow-up period.ConclusionsAzelnidipine was more effective for controlling blood pressure than Trichlormethiazide in Japanese type 2 diabetes patients, whereas Trichlormethiazide was more effective for reducing albuminuria than azelnidipine. Both of these agents, however, similarly exacerbated glycemic control in type 2 diabetic patients with hypertension.Trial RegistrationUMIN 000006081.
-
Flow chart of study participants throughout the trial.
2015Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo TerauchiAbstract:Of the 250 patients who were enrolled, 209 patients (azelnidipine group: 103 patients, Trichlormethiazide group: 106 patients) completed the trial. Seventeen patients in the azelnidipine group and fourteen patients in the Trichlormethiazide group were excluded because they were lost-to-follow-up or because of missing data.
-
Time courses for clinical parameters in the azelnidipine group and the Trichlormethiazide group.
2015Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo TerauchiAbstract:The parameters are described as “mean ± SD” at 0, 24, and 48 weeks. The differences in parameters at 24 and 48 weeks relative to the baseline values (0 weeks) were analyzed using a paired t-test (*P < 0.05, **P < 0.01) or a Wilcoxon signed rank test (†P < 0.05, ††P < 0.01).Time courses for clinical parameters in the azelnidipine group and the Trichlormethiazide group.
-
RESEARCH ARTICLE Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial
2014Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo Terauchi, Citation Takihata M, Nakamura A, Kondo Y, Kawasaki SAbstract:Objective This study compared the efficacy and safety of azelnidipine with that of Trichlormethiazide in Japanese type 2 diabetic patients with hypertension. Methods In a multicenter, open-label trial, 240 patients with adequately controlled diabetes (HbA1c 7.0%) under lifestyle modification and/or administration of hypoglycemic agents and inade-quately controlled hypertension (systolic blood pressure [sBP] 130 mmHg or diastolic blood pressure [dBP] 80 mmHg) who were being treated with olmesartan were enrolled. Participants were randomly assigned to an azelnidipine group or a Trichlormethiazide group and were followed up for 48 weeks. Main outcome measure was the difference in the change in HbA1c levels from the baseline values at 48 weeks between these two groups. Results Of the 240 subjects that were enrolled, 209 subjects (azelnidipine group: 103 patients, tri-chlormethiazide group: 106 patients) completed this trial. At 48 weeks, the following changes were observed in the azelnidipine and Trichlormethiazide groups, respectively: HbA1c levels, 0.19 ± 0.52 % and 0.19 ± 0.54%; sBP/dBP,-10.7 ± 9.6/-6.6 ± 6.6 mmHg and-7.1 ± 7.7/-3.3 ± 6.1 mmHg (P < 0.001 for both sBP and dBP). In both groups, dizziness (12 patients [11.7%] and 16 patients [15.1%]) and edema (16 patients [15.5%] and 7 patients [6.6%], P = 0.047) were observed during the 48-week follow-up period
Masahiro Takihata - One of the best experts on this subject based on the ideXlab platform.
-
comparison of azelnidipine and Trichlormethiazide in japanese type 2 diabetic patients with hypertension the coat randomized controlled trial
PLOS ONE, 2015Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo TerauchiAbstract:Objective This study compared the efficacy and safety of azelnidipine with that of Trichlormethiazide in Japanese type 2 diabetic patients with hypertension.
-
Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial
2015Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo TerauchiAbstract:ObjectiveThis study compared the efficacy and safety of azelnidipine with that of Trichlormethiazide in Japanese type 2 diabetic patients with hypertension.MethodsIn a multicenter, open-label trial, 240 patients with adequately controlled diabetes (HbA1c ≤ 7.0%) under lifestyle modification and/or administration of hypoglycemic agents and inadequately controlled hypertension (systolic blood pressure [sBP] ≥ 130 mmHg or diastolic blood pressure [dBP] ≥ 80 mmHg) who were being treated with olmesartan were enrolled. Participants were randomly assigned to an azelnidipine group or a Trichlormethiazide group and were followed up for 48 weeks. Main outcome measure was the difference in the change in HbA1c levels from the baseline values at 48 weeks between these two groups.ResultsOf the 240 subjects that were enrolled, 209 subjects (azelnidipine group: 103 patients, Trichlormethiazide group: 106 patients) completed this trial. At 48 weeks, the following changes were observed in the azelnidipine and Trichlormethiazide groups, respectively: HbA1c levels, 0.19 ± 0.52% and 0.19 ± 0.54%; sBP/dBP, -10.7 ± 9.6/-6.6 ± 6.6 mmHg and -7.1 ± 7.7/-3.3 ± 6.1 mmHg (P < 0.001 for both sBP and dBP). In both groups, dizziness (12 patients [11.7%] and 16 patients [15.1%]) and edema (16 patients [15.5%] and 7 patients [6.6%], P = 0.047) were observed during the 48-week follow-up period.ConclusionsAzelnidipine was more effective for controlling blood pressure than Trichlormethiazide in Japanese type 2 diabetes patients, whereas Trichlormethiazide was more effective for reducing albuminuria than azelnidipine. Both of these agents, however, similarly exacerbated glycemic control in type 2 diabetic patients with hypertension.Trial RegistrationUMIN 000006081.
-
Flow chart of study participants throughout the trial.
2015Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo TerauchiAbstract:Of the 250 patients who were enrolled, 209 patients (azelnidipine group: 103 patients, Trichlormethiazide group: 106 patients) completed the trial. Seventeen patients in the azelnidipine group and fourteen patients in the Trichlormethiazide group were excluded because they were lost-to-follow-up or because of missing data.
-
Time courses for clinical parameters in the azelnidipine group and the Trichlormethiazide group.
2015Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo TerauchiAbstract:The parameters are described as “mean ± SD” at 0, 24, and 48 weeks. The differences in parameters at 24 and 48 weeks relative to the baseline values (0 weeks) were analyzed using a paired t-test (*P < 0.05, **P < 0.01) or a Wilcoxon signed rank test (†P < 0.05, ††P < 0.01).Time courses for clinical parameters in the azelnidipine group and the Trichlormethiazide group.
-
RESEARCH ARTICLE Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial
2014Co-Authors: Masahiro Takihata, Akinobu Nakamura, Yoshinobu Kondo, Satsuki Kawasaki, Mari Kimura, Yasuo Terauchi, Citation Takihata M, Nakamura A, Kondo Y, Kawasaki SAbstract:Objective This study compared the efficacy and safety of azelnidipine with that of Trichlormethiazide in Japanese type 2 diabetic patients with hypertension. Methods In a multicenter, open-label trial, 240 patients with adequately controlled diabetes (HbA1c 7.0%) under lifestyle modification and/or administration of hypoglycemic agents and inade-quately controlled hypertension (systolic blood pressure [sBP] 130 mmHg or diastolic blood pressure [dBP] 80 mmHg) who were being treated with olmesartan were enrolled. Participants were randomly assigned to an azelnidipine group or a Trichlormethiazide group and were followed up for 48 weeks. Main outcome measure was the difference in the change in HbA1c levels from the baseline values at 48 weeks between these two groups. Results Of the 240 subjects that were enrolled, 209 subjects (azelnidipine group: 103 patients, tri-chlormethiazide group: 106 patients) completed this trial. At 48 weeks, the following changes were observed in the azelnidipine and Trichlormethiazide groups, respectively: HbA1c levels, 0.19 ± 0.52 % and 0.19 ± 0.54%; sBP/dBP,-10.7 ± 9.6/-6.6 ± 6.6 mmHg and-7.1 ± 7.7/-3.3 ± 6.1 mmHg (P < 0.001 for both sBP and dBP). In both groups, dizziness (12 patients [11.7%] and 16 patients [15.1%]) and edema (16 patients [15.5%] and 7 patients [6.6%], P = 0.047) were observed during the 48-week follow-up period
Sadayoshi Ito - One of the best experts on this subject based on the ideXlab platform.
-
angiotensin ii type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy
Hypertension, 2006Co-Authors: Susumu Ogawa, Takefumi Mori, Kazuhiro Nako, Taro Kato, Kazuhisa Takeuchi, Sadayoshi ItoAbstract:We tested the hypothesis that blockade of angiotensin II type 1 receptors reduces oxidative stress markers in parallel with urinary albumin and type IV collagen excretions. Sixty-six diabetic patients with nephropathy were randomly assigned to either the angiotensin II receptor blocker (ARB; n=33) or Trichlormethiazide (n=33) group. The majority of patients had been treated with angiotensin-converting enzyme inhibitors or calcium channel blockers for > or =1 year before the present study. Reduction of blood pressure was not different between the 2 groups, and HbA1c levels did not change over the study period (8 weeks). Treatment with ARB (candesartan 8 mg/day, n=11 or valsartan 80 mg/day, n=22) for 8 weeks reduced the levels of plasma monocyte chemoattractant protein 1, interleukin 6, urinary 8-epi-prostaglandin F2alpha, 8-hydroxydeoxyguanosine, albumin, and type IV collagen, whereas the levels of these markers were not altered with Trichlormethiazide (2 mg/day). Significant correlation was observed between the reduction of the urinary 8-epi- prostaglandin F2alpha and 8-hydroxydeoxyguanosine and those of the urinary albumin and type IV collagen. Subjects with large oxidative stress had large reduction rates because of ARB administration and showed large urinary albumin suppression. These results suggest that ARBs reduce oxidative stress and inflammation in diabetic patients independent of their effects on blood pressure. In addition, increases in oxidative stress caused by angiotensin II may play an important role in the progression of diabetic nephropathy. Our results may help to explain the clinical observation that ARB reduces urinary albumin excretion very efficiently in some patients but not in others.
-
a case of exercise induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and Trichlormethiazide
Hypertension Research, 2003Co-Authors: Osamu Ito, Sadayoshi Ito, Yutaka Hasegawa, Kazuto Sato, Hideaki Mitsui, Fumiaki Yuda, Hiroshi Sato, Kenichi KudoAbstract:Exercise-induced acute renal failure (ARF) developed in a 45-year-old man during antihypertensive therapy with losartan and Trichlormethiazide. The antihypertensive therapy was stopped and marked hypouricemia became apparent during improvement of his renal function. The daily urinary excretion of uric acid was normal and an increased fractional excretion of uric acid was observed. Renal biopsy revealed that the kidney was recovering from acute tubular necrosis with interstitial fibrosis. Based on the results of pyrazinamide and benzbromarone tests, we classified this case as one of presecretory reabsorption defect of uric acid. Antihypertesive therapy with benidipine and candesartan was initiated, and the patient has not had any ARF episodes since. Because idiopathic renal hypouricemia can be associated with exercise-induced ARF and chronic renal dysfunction, careful antihypertensive therapy and follow-up evaluation of renal function might be necessary for hypertensive patients with idiopathic renal hypouricemia. (Hypertens Res 2003; 26: 509-513)
Hajime M Koyano - One of the best experts on this subject based on the ideXlab platform.
-
comparison of effects of azelnidipine and Trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type 2 diabetic patients
Journal of Diabetes Investigation, 2011Co-Authors: Hidenori Yoshii, Tomoya Mita, Junko Sato, Yuuki Kodama, Jong Bock Choi, Koji Komiya, Kazuhisa Matsumoto, Rei Kanno, Masahiko Kawasumi, Hajime M KoyanoAbstract:Aims/Introduction: Angiotensin II type 1 receptor blockers (ARB) are regarded as first-line treatment for type 2 diabetes with hypertension. However, lowering blood pressure to the target level often requires more than one antihypertensive agent as recommended by the guideline. In this open-label, prospective, crossover clinical trial, we compared the effects of combination treatment of ARB with a calcium channel blocker (CCB) or with a low-dose thiazide diuretic on blood pressure (BP) and various metabolic parameters in hypertensive patients with type 2 diabetes. Materials and Methods: A total of 39 Japanese type 2 diabetics with hypertension treated with olmesartan (20 mg/day) for at least 8 weeks were recruited to this study. At study entry, treatment was switched to either olmesartan (20 mg/day)/azelnidipine (16 mg/day) or olmesartan (20 mg/day)/Trichlormethiazide (1 mg/day) and continued for 12 weeks. Then, the drugs were switched and treatment was continued for another 12 weeks. We measured clinical blood pressure and various metabolic parameters before and at the end of each study arm. Results: Compared with the olmesartan/Trichlormethiazide treatment, treatment with olmesartan/azelnidipine achieved superior clinical blood pressure and pulse rate control. In contrast, the treatment with olmesartan/Trichlormethiazide resulted in increased HbA1c, serum uric acid and worsening of estimated glomerular filtration rate, though there were no differences in other metabolic parameters including urine 8-hydroxy-2′-deoxyguanosine, C-reactive protein and adiponectin between the two treatments. Conclusions: Our results show that the combination of ARB with azelnidipine is more beneficial with regard to blood pressure control and metabolic outcome than the combination of olmesartan with low dose Trichlormethiazide. This trial was registered with UMIN clinical trial registry (no. UMIN000005064). (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00135.x, 2011)
Kenichi Kudo - One of the best experts on this subject based on the ideXlab platform.
-
a case of exercise induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and Trichlormethiazide
Hypertension Research, 2003Co-Authors: Osamu Ito, Sadayoshi Ito, Yutaka Hasegawa, Kazuto Sato, Hideaki Mitsui, Fumiaki Yuda, Hiroshi Sato, Kenichi KudoAbstract:Exercise-induced acute renal failure (ARF) developed in a 45-year-old man during antihypertensive therapy with losartan and Trichlormethiazide. The antihypertensive therapy was stopped and marked hypouricemia became apparent during improvement of his renal function. The daily urinary excretion of uric acid was normal and an increased fractional excretion of uric acid was observed. Renal biopsy revealed that the kidney was recovering from acute tubular necrosis with interstitial fibrosis. Based on the results of pyrazinamide and benzbromarone tests, we classified this case as one of presecretory reabsorption defect of uric acid. Antihypertesive therapy with benidipine and candesartan was initiated, and the patient has not had any ARF episodes since. Because idiopathic renal hypouricemia can be associated with exercise-induced ARF and chronic renal dysfunction, careful antihypertensive therapy and follow-up evaluation of renal function might be necessary for hypertensive patients with idiopathic renal hypouricemia. (Hypertens Res 2003; 26: 509-513)
